SG11201408761VA - Purification of iduronate-2-sulfatase - Google Patents
Purification of iduronate-2-sulfataseInfo
- Publication number
- SG11201408761VA SG11201408761VA SG11201408761VA SG11201408761VA SG11201408761VA SG 11201408761V A SG11201408761V A SG 11201408761VA SG 11201408761V A SG11201408761V A SG 11201408761VA SG 11201408761V A SG11201408761V A SG 11201408761VA SG 11201408761V A SG11201408761V A SG 11201408761VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lllll
- llll
- massachusetts
- publication
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/005014 A3 (51) International Patent Classification: C07K1/00 (2006.01) A61K38/17 (2006.01) C07K16/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) (26) Publication (30) Priority Filing Language: Language: PCT/US2013/048561 28 June 2013 (28.06.2013) English Data: 61/666,733 29 June 2012 (29.06.2012) English US (71) Applicant: SHIRE HUMAN GENETIC THERAPIES, INC. [US/US]; 300 Shire Way, Lexington, Massachusetts 02421 (US). (72) Inventor: NICHOLS, Dave; 300 Shire Way, Lexington, Massachusetts 02421 (US). (74) Agent: HUDDLESON, Justin P.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, [Continued on next page] (54) Title: PURIFICATION OF IDURONATE-2-SULFATASE < o © o (57) Abstract: The present invention provides, among other things, im proved methods for purifying 12 S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture me dium, using a process involving as few as four chromatography columns. FIG. 1 WO 2014/005014 A3 I lllll llllllll II llllll III III lllll lllll lllll llll lllll III III lllll lllll llll lllllll llll llll llll KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 27 February 2014
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666733P | 2012-06-29 | 2012-06-29 | |
| PCT/US2013/048561 WO2014005014A2 (en) | 2012-06-29 | 2013-06-28 | Purification of iduronate-2-sulfatase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408761VA true SG11201408761VA (en) | 2015-01-29 |
Family
ID=49778401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408761VA SG11201408761VA (en) | 2012-06-29 | 2013-06-28 | Purification of iduronate-2-sulfatase |
| SG10201703489VA SG10201703489VA (en) | 2012-06-29 | 2013-06-28 | Purification of iduronate-2-sulfatase |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201703489VA SG10201703489VA (en) | 2012-06-29 | 2013-06-28 | Purification of iduronate-2-sulfatase |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US9051556B2 (en) |
| EP (2) | EP2867245B1 (en) |
| JP (4) | JP6171007B2 (en) |
| KR (5) | KR101380740B1 (en) |
| CN (3) | CN107596357A (en) |
| AR (1) | AR091647A1 (en) |
| AU (3) | AU2013282395C1 (en) |
| BR (1) | BR112014032567B1 (en) |
| CA (2) | CA2877517C (en) |
| CL (1) | CL2014003567A1 (en) |
| CO (1) | CO7240396A2 (en) |
| CR (1) | CR20140588A (en) |
| CY (1) | CY1121519T1 (en) |
| DK (1) | DK2867245T3 (en) |
| DO (1) | DOP2014000294A (en) |
| EA (2) | EA202090044A1 (en) |
| ES (1) | ES2689468T3 (en) |
| GT (1) | GT201400303A (en) |
| HK (4) | HK1209431A1 (en) |
| HR (1) | HRP20181897T1 (en) |
| HU (1) | HUE040769T2 (en) |
| IL (4) | IL236315A (en) |
| LT (1) | LT2867245T (en) |
| MX (3) | MX336715B (en) |
| MY (3) | MY157087A (en) |
| NZ (3) | NZ733366A (en) |
| PE (1) | PE20150720A1 (en) |
| PH (3) | PH12014502871B1 (en) |
| PL (1) | PL2867245T3 (en) |
| PT (1) | PT2867245T (en) |
| RS (1) | RS58005B1 (en) |
| SG (2) | SG11201408761VA (en) |
| SI (1) | SI2867245T1 (en) |
| TR (1) | TR201815811T4 (en) |
| TW (2) | TWI587869B (en) |
| UA (1) | UA121959C2 (en) |
| WO (1) | WO2014005014A2 (en) |
| ZA (2) | ZA201409397B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8974791B2 (en) | 2007-07-27 | 2015-03-10 | Armagen Technologies, Inc. | Methods and compositions for increasing α-L-iduronidase activity in the CNS |
| US8834874B2 (en) | 2009-10-09 | 2014-09-16 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS |
| KR101158673B1 (en) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (en) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | Purification of iduronate-2-sulfatase |
| WO2018038243A1 (en) | 2016-08-25 | 2018-03-01 | Ｊｃｒファーマ株式会社 | Method for producing antibody fusion protein |
| CN106282231B (en) * | 2016-09-06 | 2020-01-03 | 陕西慧康生物科技有限责任公司 | Construction method and application of mucopolysaccharide storage disease type II animal model |
| CN106428420B (en) * | 2016-10-17 | 2018-08-21 | 上海江南长兴造船有限责任公司 | A method of being used for the installation of super-container vessel crack arrest steel hatch coaming |
| BR112020005271A2 (en) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | protein, polypeptide, polynucleotide, vector, host cell, method for producing a polypeptide, methods of treating a disorder, reducing accumulation, monitoring, transporting an agent and treating an lsd and pharmaceutical composition |
| WO2020132452A1 (en) * | 2018-12-20 | 2020-06-25 | Shire Human Genetic Therapies, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
| US20240052327A1 (en) * | 2020-10-23 | 2024-02-15 | Alexion Pharmaceuticals, Inc. | Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase |
| AU2022218782A1 (en) | 2021-02-12 | 2023-08-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK6488D0 (en) | 1988-01-07 | 1988-01-07 | Novo Industri As | ENZYMES |
| US5310646A (en) | 1988-05-13 | 1994-05-10 | Regents Of The University Of Minnesota | Method for the detection of mucopolysaccharide storage diseases |
| US5932211A (en) * | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
| AU700369B2 (en) | 1994-03-16 | 1999-01-07 | Regents Of The University Of California, The | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| DE19527054A1 (en) | 1995-07-26 | 1997-01-30 | Behringwerke Ag | Method for characterizing the glycosylation of glycoproteins and for in-vitro determination of the bioavailability of glycoproteins |
| EP2221361A3 (en) | 1996-08-30 | 2011-02-09 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US7083793B2 (en) | 1999-02-26 | 2006-08-01 | Millennium Pharmaceuticals, Inc. | Tango 243 polypeptides and uses thereof |
| EP1179000A4 (en) | 1999-02-26 | 2005-10-12 | Millennium Pharm Inc | Secreted proteins and uses thereof |
| IL145893A0 (en) | 1999-04-26 | 2002-07-25 | Genentech Inc | Cell culture process for glycoproteins |
| JP2002017376A (en) | 1999-07-08 | 2002-01-22 | Herikkusu Kenkyusho:Kk | Secretory protein or membrane protein |
| JP2003508088A (en) | 1999-09-03 | 2003-03-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 52 human secreted proteins |
| US6780627B1 (en) | 2000-01-31 | 2004-08-24 | Millennium Pharmaceuticals, Inc. | 22438, 23553, 25278, and 26212 novel human sulfatases |
| AU2001238488A1 (en) | 2000-02-17 | 2001-08-27 | Incyte Genomics, Inc. | Human kinases |
| WO2001070804A1 (en) | 2000-03-17 | 2001-09-27 | Human Genome Sciences, Inc. | 7 human ovarian and ovarian cancer associated proteins |
| EP2295456A1 (en) | 2000-04-12 | 2011-03-16 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20030148920A1 (en) | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
| AU2002317700A1 (en) | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
| JP4319979B2 (en) | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | Non-affinity purification of proteins |
| US6890736B1 (en) | 2002-09-20 | 2005-05-10 | Immunex Corporation | Methods for producing proteins in cultured cells |
| CN101044239B (en) * | 2002-12-23 | 2010-12-08 | 布里斯托尔-迈尔斯斯奎布公司 | Mammalian cell culture processes for protein production |
| JP4606712B2 (en) * | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2-O sulfatase compositions and related methods |
| ATE534730T1 (en) | 2003-02-11 | 2011-12-15 | Shire Human Genetic Therapies | DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DISEASES AND OTHERS USING AN ENZYME THAT PRODUCES FORMYLGLYCIN |
| US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
| NZ589037A (en) | 2004-01-30 | 2011-10-28 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
| WO2005113765A2 (en) | 2004-05-06 | 2005-12-01 | Biomarin Pharmaceutical Inc. | Methods of activation of sulfatases and methods and compositions of using the same |
| SI2267024T1 (en) | 2005-06-03 | 2012-09-28 | Ares Trading Sa | Production of recombinant Il-18 binding protein |
| KR20080111487A (en) | 2006-03-20 | 2008-12-23 | 메다렉스, 인코포레이티드 | Protein purification |
| JP4458377B2 (en) | 2007-06-29 | 2010-04-28 | キヤノン株式会社 | Process cartridge and electrophotographic image forming apparatus |
| US20130195888A1 (en) | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
| ES2984846T3 (en) * | 2008-01-18 | 2024-10-31 | Biomarin Pharm Inc | Manufacture of highly phosphorylated, active human lysosomal sulfatase enzymes and their uses |
| US8834874B2 (en) | 2009-10-09 | 2014-09-16 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS |
| WO2011108451A1 (en) * | 2010-03-01 | 2011-09-09 | 日本ケミカルリサーチ株式会社 | Method for producing recombinant lysosomal enzymes using gene knockout cells |
| NZ702801A (en) * | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
| AU2011270669B2 (en) | 2010-06-25 | 2017-01-05 | Takeda Pharmaceutical Company Limited | Methods and compositions for CNS delivery of iduronate-2-sulfatase |
| AR082319A1 (en) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES |
| EP2623118A4 (en) * | 2010-09-28 | 2014-05-07 | Kyoritsu Seiyaku Corp | Mucosal adjuvant composition |
| WO2012101671A1 (en) | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| WO2012105954A1 (en) | 2011-01-31 | 2012-08-09 | Hewlett-Packard Development Company, L. P. | A diffuser with a dynamically tunable scattering angle |
| KR101158673B1 (en) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| US20140004097A1 (en) | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (en) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | Purification of iduronate-2-sulfatase |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| KR20190062745A (en) | 2017-11-29 | 2019-06-07 | 주식회사 위니플 | Shopping mall mobile app builder |
-
2012
- 2012-09-07 KR KR1020120099511A patent/KR101380740B1/en active IP Right Grant
-
2013
- 2013-03-14 US US13/829,706 patent/US9051556B2/en active Active
- 2013-06-28 CN CN201710840314.6A patent/CN107596357A/en active Pending
- 2013-06-28 CN CN201380042665.2A patent/CN104583225A/en active Pending
- 2013-06-28 HU HUE13809853A patent/HUE040769T2/en unknown
- 2013-06-28 MX MX2015000190A patent/MX336715B/en unknown
- 2013-06-28 EP EP13809853.8A patent/EP2867245B1/en not_active Revoked
- 2013-06-28 MY MYPI2014003472A patent/MY157087A/en unknown
- 2013-06-28 EP EP18193801.0A patent/EP3441398A1/en active Pending
- 2013-06-28 LT LTEP13809853.8T patent/LT2867245T/en unknown
- 2013-06-28 CA CA2877517A patent/CA2877517C/en active Active
- 2013-06-28 EA EA202090044A patent/EA202090044A1/en unknown
- 2013-06-28 CA CA3008945A patent/CA3008945A1/en not_active Abandoned
- 2013-06-28 MY MYPI2016000157A patent/MY180287A/en unknown
- 2013-06-28 MY MYPI2019006401A patent/MY192068A/en unknown
- 2013-06-28 TW TW105120026A patent/TWI587869B/en active
- 2013-06-28 SG SG11201408761VA patent/SG11201408761VA/en unknown
- 2013-06-28 MX MX2016001228A patent/MX366906B/en unknown
- 2013-06-28 SG SG10201703489VA patent/SG10201703489VA/en unknown
- 2013-06-28 SI SI201331176T patent/SI2867245T1/en unknown
- 2013-06-28 TR TR2018/15811T patent/TR201815811T4/en unknown
- 2013-06-28 PT PT13809853T patent/PT2867245T/en unknown
- 2013-06-28 BR BR112014032567-7A patent/BR112014032567B1/en active IP Right Grant
- 2013-06-28 CN CN201710840704.3A patent/CN107596358A/en active Pending
- 2013-06-28 JP JP2015520567A patent/JP6171007B2/en active Active
- 2013-06-28 NZ NZ733366A patent/NZ733366A/en unknown
- 2013-06-28 PL PL13809853T patent/PL2867245T3/en unknown
- 2013-06-28 EA EA201492177A patent/EA034549B1/en active IP Right Maintenance
- 2013-06-28 RS RS20181324A patent/RS58005B1/en unknown
- 2013-06-28 TW TW102123353A patent/TWI553120B/en active
- 2013-06-28 PE PE2014002539A patent/PE20150720A1/en active IP Right Grant
- 2013-06-28 WO PCT/US2013/048561 patent/WO2014005014A2/en active Application Filing
- 2013-06-28 DK DK13809853.8T patent/DK2867245T3/en active
- 2013-06-28 NZ NZ703093A patent/NZ703093A/en unknown
- 2013-06-28 ES ES13809853.8T patent/ES2689468T3/en active Active
- 2013-06-28 UA UAA201413826A patent/UA121959C2/en unknown
- 2013-06-28 NZ NZ743910A patent/NZ743910A/en unknown
- 2013-06-28 AU AU2013282395A patent/AU2013282395C1/en active Active
- 2013-07-01 AR ARP130102350 patent/AR091647A1/en not_active Application Discontinuation
- 2013-09-26 KR KR1020130114704A patent/KR20140004603A/en active Search and Examination
-
2014
- 2014-12-17 IL IL236315A patent/IL236315A/en active IP Right Grant
- 2014-12-17 CR CR20140588A patent/CR20140588A/en unknown
- 2014-12-19 ZA ZA201409397A patent/ZA201409397B/en unknown
- 2014-12-19 DO DO2014000294A patent/DOP2014000294A/en unknown
- 2014-12-22 PH PH12014502871A patent/PH12014502871B1/en unknown
- 2014-12-26 CO CO14284199A patent/CO7240396A2/en unknown
- 2014-12-29 CL CL2014003567A patent/CL2014003567A1/en unknown
- 2014-12-29 GT GT201400303A patent/GT201400303A/en unknown
-
2015
- 2015-01-07 MX MX2019008914A patent/MX2019008914A/en unknown
- 2015-03-30 US US14/673,607 patent/US9492511B2/en active Active
- 2015-10-14 HK HK15110042.0A patent/HK1209431A1/en unknown
- 2015-10-16 PH PH12015502408A patent/PH12015502408A1/en unknown
- 2015-10-28 HK HK15110643.3A patent/HK1209767A1/en unknown
-
2016
- 2016-01-27 AU AU2016200469A patent/AU2016200469B2/en active Active
- 2016-03-24 JP JP2016060910A patent/JP6505629B2/en active Active
- 2016-09-28 US US15/279,018 patent/US10344270B2/en active Active
- 2016-11-03 IL IL248727A patent/IL248727A0/en active IP Right Grant
-
2018
- 2018-01-11 AU AU2018200230A patent/AU2018200230B2/en active Active
- 2018-03-30 JP JP2018067404A patent/JP2018121645A/en not_active Withdrawn
- 2018-05-17 ZA ZA2018/03289A patent/ZA201803289B/en unknown
- 2018-07-05 HK HK18108734.4A patent/HK1249027A1/en unknown
- 2018-07-05 HK HK18108732.6A patent/HK1249026A1/en unknown
- 2018-08-21 IL IL261264A patent/IL261264B/en unknown
- 2018-11-14 HR HRP20181897TT patent/HRP20181897T1/en unknown
- 2018-11-28 CY CY20181101263T patent/CY1121519T1/en unknown
-
2019
- 2019-05-20 US US16/417,440 patent/US20190359958A1/en not_active Abandoned
- 2019-05-28 KR KR1020190062745A patent/KR20190064542A/en active Application Filing
-
2020
- 2020-01-02 PH PH12020500027A patent/PH12020500027A1/en unknown
- 2020-03-05 JP JP2020037811A patent/JP2020105209A/en active Pending
- 2020-11-06 US US17/092,034 patent/US11530393B2/en active Active
- 2020-12-16 KR KR1020200176714A patent/KR20200143339A/en not_active IP Right Cessation
-
2021
- 2021-10-06 IL IL287057A patent/IL287057A/en unknown
- 2021-12-28 KR KR1020210189927A patent/KR20220002227A/en not_active Application Discontinuation
-
2022
- 2022-11-03 US US18/052,442 patent/US20240043817A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408761VA (en) | Purification of iduronate-2-sulfatase | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201807188VA (en) | Modified cells for immunotherapy | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof |